Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | DPP3 | Q9NY33 | 4/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | CCKAR | P32238 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.48 |
| ▸ | ITGAL | P20701 | 2/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.48 |
| ▸ | BRS3 | P32247 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30478003 | 0.91 | DPP3 (0.52) | BCHECYP2C19DPP3DPP4CCKAR | |
| SCHEMBL15692330 | 0.90 | BCHE (0.63) | BCHECYP2C19DPP3DPP4OPRM1 | |
| SCHEMBL30051339 | 0.88 | DPP4 (0.58) | BCHECYP2C19DPP3DPP4TSHR | |
| SCHEMBL30051406 | 0.87 | DPP3 (0.58) | BCHECYP2C19DPP3DPP4ITGB2 | |
| SCHEMBL29966903 | 0.86 | DPP4 (0.54) | BCHECYP2C19DPP3DPP4CCKBR | |
| SCHEMBL30051392 | 0.86 | DPP3 (0.67) | BCHECYP2C19DPP3DPP4 | |
| SCHEMBL29420134 | 0.86 | DPP3 (0.57) | BCHECYP2C19DPP3DPP4OPRM1 | |
| SCHEMBL30052289 | 0.86 | DPP3 (0.59) | BCHEDPP3DPP4 | |
| SCHEMBL21556145 | 0.86 | DPP3 (0.49) | BCHEDPP3DPP4CCKARCCKBR | |
| SCHEMBL6879435 | 0.85 | DPP3 (0.53) | BCHEDPP3DPP4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-3515928-B1 | UNSTRUCTURED NON-REPETITIVE POLYPEPTIDES HAVING LCST BEHAVIOR | UNIV DUKE (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12084480-B2 | Unstructured non-repetitive polypeptides having lcst behavior | DUKE UNIVERSITY (US) | 2024-09-10 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-20220098248-A1 | UNSTRUCTURED NON-REPETITIVE POLYPEPTIDES HAVING LCST BEHAVIOR | DUKE UNIVERSITY | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | BCHE 353/4885CYP2C19 212/4885DPP3 25/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | BCHE 231/4885CYP2C19 699/4885DPP3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.